Achiko Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Steven Goh

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	3.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

CEO

Steven Goh (56 yo)

3.3yrs

Permanencia

US$240,000

Compensación

Mr. Wern-Yi Goh, also known as Steven, B.Com., M.B.A., is Chief Executive Officer at Achiko AG since July 29, 2020 and has been its Director since 2019. He is a serial entrepreneur. He has founded/co-found...

Achiko Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Achiko AG Announces Chief Financial Officer Changes

Achiko AG Appoints Derek Brand to Advisory Board

Achiko AG, Annual General Meeting, Jun 27, 2022

Achiko AG Announces Executive Changes

Achiko AG Expands Advisory Board

Achiko AG Announces Appointment to Its Advisory Board

Recent updates

Achiko AG(SWX:ACHI) dropped from Swiss Performance Index (Price Return)

New major risk - Financial data availability

Achiko AG Completes Production Test with PT Indofarma Tbk as a Precursor to Mass Production of Its Generation 2 AptameX Covid-19 Test Kit

Achiko AG Announces Chief Financial Officer Changes

Achiko AG announced that it has received CHF 1.3 million in funding from Buranto AG

Achiko AG to Report Fiscal Year 2021 Results on Jun 06, 2022

Achiko AG announced that it expects to receive CHF 1.25 million in funding from Negma Group Ltd., Buranto AG

Achiko AG Appoints Derek Brand to Advisory Board

Achiko AG, Annual General Meeting, Jun 27, 2022

Achiko AG Expects to Have AptameX in Widespread Commercial Availability in Third Quarter of 2022

Achiko AG announced that it expects to receive CHF 12 million in funding from Riverfort Global Opportunities Pcc Ltd

Achiko AG Reports Calibration Results for AptameX Covid-19 Rapid Test Technology

Achiko AG Announce Optimised Second-Generation Covid-19 Diagnostic Test Received Full Product Registration Approval in Indonesia

Achiko's Covid-19 Dna Aptamer-Based Rapid Testing Platform Update

Achiko AG announced that it has received CHF 3.45 million in funding from OCS International Commodities & Investments FZCO and other investors

Achiko's Rapid Covid-19 Diagnostic Test AptameX Receives Product and Registration Approval from Indonesia's Ministry of Health

Chief Financial Officer ad Interim has left the company

Member of Advisory Board has left the company

Achiko AG announced that it has received CHF 0.9 million in funding from Negma Group Ltd.

Achiko AG Establishes A Joint Venture with PT Indonesia Farma Medis for the Production and Distribution of Its Test Platform for Covid-19 in Indonesia

Achiko AG Concludes Phase 1 Study of Project Gumnuts for Covid-19 Testing

Achiko AG Announces Executive Changes

Achiko Partners with Udayana University for Covid-19 Testing Research in Bali, Indonesia

Achiko AG announced that it expects to receive CHF 2 million in funding from Negma Group Ltd.

Achiko AG announced that it expects to receive $2.5 million in funding from Yorkville Advisors Global LP

Achiko AG Expands Advisory Board

Achiko AG Announces Appointment to Its Advisory Board

First half earnings released

New 90-day high - CHF0.92

Negma Group Ltd. acquired an additional 7.58% stake in Achiko AG (SWX:ACHI).

Achiko AG announced that it has received $4 million in funding from PT. Media Nusantara Citra Tbk

CEO

Permanencia

Compensación